HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Pierre-Emmanuel Falcoz Permission Requests Google Scholar Articles by Falcoz, P.-E. PubMed Articles by Falcoz, P.-E. Related Collections Lung - cancer Related Article

---

Original Articles: General Thoracic

Invited Commentary

Department of Thoracic and Cardiovascular Surgery, Jean Minjoz Hospital, Blvd Fleming, Besançon 25000, France

(Email: pierre-emmanuel.falcoz@wanadoo.fr).

The first 20% of the full text of this article appears below.

In the present article, Mansour and associates [1] seek to address the very controversial and provocative questions of the optimal management of patients with persistent N2 disease and the impact of pneumonectomy after induction therapy. In a retrospective cohort of 153 patients having undergone pneumonectomy for nonsmall cell lung cancer, three groups were classified according to their pN2 status with respect to induction therapy: (1) persistent N2 after induction therapy, (2) pathologic stage N0 or N1 after induction therapy (downstaged patients), and (3) pathologic N2 disease with immediate surgery. The results showed no statistical difference in operative . . . [Full Text of this Article]

Related Article

Persistent N2 Disease After Induction Therapy Does Not Jeopardize Early and Medium Term Outcomes of Pneumonectomy

Ziad Mansour, Evgenia A. Kochetkova, Nicola Santelmo, Xavier Ducrocq, Elisabeth Quoix, Jean-Marie Wihlm, and Gilbert Massard
Ann. Thorac. Surg. 2008 86: 228-233. [Abstract] [Full Text] [PDF]